For two decades a type of rail tanker that could tear open in the event of an accident has been used to haul hazardous liquids across the country.
By Jason Keyser,?Associated Press / September 12, 2012
A freight train is seen after an early morning derailment in Columbus, Ohio on July 11. Part of the freight train carrying ethanol derailed and caught fire, shooting flames skyward into the darkness and prompting the evacuation of a mile-wide area as firefighters and hazardous materials crews monitored the blaze.
Eamon Queeney/The Columbus Dispatch/AP/File
Enlarge
For two decades, one of the most commonly used types of rail tanker has been allowed to haul hazardous liquids from coast to coast even though transportation officials were aware of a dangerous design flaw that almost guarantees the car will tear open in an accident, potentially spilling cargo that could catch fire, explode or contaminate the environment.
Click Here for your FREE 30 DAYS of The Christian Science Monitor Weekly Digital Edition
The rail and chemical industries have committed to a safer design for new tankers but are pressing regulators not to require modifications to tens of thousands of existing cars, despite a spike in the number of accidents as more tankers are put into service to accommodate soaring demand for ethanol, the highly flammable corn-based fuel usually transported by rail.
Derailments have triggered chemical spills and massive blasts like one in July in Columbus, Ohio, that blew up with such intensity that one witness said it "looked like the sun exploded." Some communities with busy railways are beginning to regard the tankers as a serious threat to public safety.
"There's a law of averages that gives me great concern," said Jim Arie, fire chief in Barrington, a wealthy Chicago suburb where ethanol tankers snake through a bustling downtown. "Sometimes I don't sleep well at night."
He's not the only one. The town's mayor is trying to build a national coalition to push for safety reforms.
The tanker, known as the DOT-111, is a workhorse of the American rail fleet, with a soda-can shape that makes it one of the most easily recognizable cars on freight routes.
The tanker itself is not suspected of causing derailments, but the National Transportation Safety Board has noted several worrisome problems: Its steel shell is too thin to resist puncture in accidents. The ends are especially vulnerable to tears from couplers that can fly up after ripping off between cars. And unloading valves and other exposed fittings on the tops of tankers can also break during rollovers.
The flaws were noted as far back as a 1991 safety study.
An Associated Press analysis of 20 years' worth of federal rail accident data found that ethanol tankers have been breached in at least 40 serious accidents since 2000. In the previous decade, there were just two breaches.
The number of severe crashes is small considering the total mileage covered by the many tankers in service, and the rail industry's safety record on hazmat shipments is strong. More than 99 percent of hazmat rail shipments arrive safely at their destinations.
"Safety is the freight railroad industry's No. 1 priority," said Patricia Reilly, senior vice president of communications at the Association of American Railroads. She said freight railroads work with experts and federal regulators to develop "rigorous standards for hazmat tank cars."
Single gene cause of insulin sensitivity may offer insight for treating diabetesPublic release date: 12-Sep-2012 [ | E-mail | Share ]
Contact: University of Oxford press office press.office@admin.ox.ac.uk 44-186-528-0530 University of Oxford
The first single gene cause of increased sensitivity to the hormone insulin has been discovered by a team of Oxford University researchers.
The opposite condition insulin resistance is a common feature of type 2 diabetes, so finding this cause of insulin sensitivity could offer new opportunities for pursuing novel treatments for diabetes.
Although mutations in the PTEN gene cause a rare condition with increased risk of cancer, the biological pathways the gene is involved in could offer promising targets for new drugs.
The Oxford University researchers, along with colleagues at the Babraham Institute in Cambridge, UK, and the Churchill Hospital in Oxford, UK, report their findings in the New England Journal of Medicine. The study was funded by the Wellcome Trust, the Medical Research Council, the National Institute for Health Research Oxford Biomedical Research Centre, and the Biotechnology and Biological Sciences Research Council.
'Insulin resistance is a major feature of type 2 diabetes,' says Dr Anna Gloyn of the Oxford Centre for Diabetes, Endocrinology and Metabolism at the University of Oxford, who led the work. 'The insulin-producing cells in the pancreas may be working hard and pumping out lots of insulin, but the body's cells no longer respond.
'Finding a genetic cause of the opposite insulin sensitivity gives us a new window on the biological processes involved. Such understanding could be important in developing new drugs that restore insulin sensitivity in type 2 diabetes.'
The PTEN gene encodes for an enzyme that is part of the insulin signalling pathway in the body. It is known to have a role in controlling the body's metabolism, and to play a part in cell growth. The Oxford team was interested in learning more about this dual role.
There is an inherited genetic condition called Cowden syndrome caused by faults in the PTEN gene. It is very rare and is thought to affect perhaps one in 200,000 people, with around 300 people with the condition in the UK. PTEN's role in cell growth sees people with Cowden syndrome develop many benign polyps in their skin, mouth and bowel, and have a higher risk than the general population of developing breast cancer, thyroid cancer and womb cancer.
'PTEN is a gene that is heavily involved in processes for both cell growth and metabolism,' says first author Dr Aparna Pal of the University of Oxford. 'Given PTEN's dual role, we were interested in understanding the metabolic profile of people with Cowden syndrome. It was possible that mutations in PTEN could improve metabolism.'
The team carried out glucose tolerance tests with 15 people with Cowden syndrome and 15 matched controls. Those with Cowden syndrome had significantly higher insulin sensitivity. In collaboration with their colleagues at the Babraham Institute, the team showed that this was caused by increased activity in the insulin signalling pathway.
The researchers also noticed that the body mass index of those with Cowden syndrome appeared greater than the controls. They carried out a comparison with a much larger control group of over 2,000 individuals from the Oxford Biobank, a data and tissue resource for research established by Professor Fredrik Karpe.
This confirmed that those with Cowden syndrome had higher levels of obesity as a group than the controls. The extra body weight appeared to be caused by extra fat, and there were no differences in where the fat was stored compared to controls.
'This was a surprise. Normally insulin sensitivity goes with being lean,' says Professor Karpe.
Dr Gloyn concludes: 'We now know that mutations that inactivate the PTEN gene result in increased cancer risk and obesity, but also increase insulin sensitivity which is very likely to protect against type 2 diabetes.
'The study shows how intimately the biological pathways governing cell growth and metabolism are linked. We need to thoroughly understand these pathways to identify which genes to target in the development of new drugs.'
She adds: 'While there are promising research avenues to pursue here, in the meantime the best way to avoid diabetes remains exercising more and eating less.'
###
Notes to Editors
* Approximately 2.9 million people are affected by diabetes in the UK, and there may be around a further 850,000 people with undiagnosed diabetes. Left untreated, diabetes can cause many different health problems including heart disease, stroke, nerve damage and blindness. Even a mildly raised glucose level can have damaging effects in the long-term.
Type 2 diabetes is by far the most common form of the disease. In the UK, about 90% of all adults with diabetes have type 2 diabetes. It occurs when the body does not produce enough insulin to control the level of glucose in the blood, and when the body is unable to use the insulin that is produced effectively. It is this second feature of type 2 diabetes that tends to be known as 'insulin resistance'. Insulin resistance is often connected with obesity.
* The paper 'PTEN mutations cause constitutive insulin sensitivity and obesity in humans' is to be published in the New England Journal of Medicine with an embargo of 22:00 UK time / 17:00 US Eastern time on Wednesday 12 September 2012.
* For almost 100 years the Medical Research Council has improved the health of people in the UK and around the world by supporting the highest quality science. The MRC invests in world-class scientists. It has produced 29 Nobel Prize winners and sustains a flourishing environment for internationally recognised research. The MRC focuses on making an impact and provides the financial muscle and scientific expertise behind medical breakthroughs, including one of the first antibiotics penicillin, the structure of DNA and the lethal link between smoking and cancer. Today MRC funded scientists tackle research into the major health challenges of the 21st century. www.mrc.ac.uk
* The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. www.wellcome.ac.uk
* The NIHR Oxford Biomedical Research Centre is funded by the National Institute for Health Research, and is a partnership between the Oxford University Hospitals Trust and the University of Oxford. The NIHR provides the NHS with the support and infrastructure it needs to conduct first-class research funded by the Government and its partners alongside high-quality patient care, education and training. Its aim is to support outstanding individuals (both leaders and collaborators), working in world class facilities (both NHS and university), and conducting leading edge research focused on the needs of patients.
* The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government's strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit the NIHR website (www.nihr.ac.uk). The views expressed in this news release are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
* The Babraham Institute, which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC), undertakes international quality life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. The institute received 22.4M investment from BBSRC in 2010-11. The Institute's research provides greater understanding of the biological events that underlie the normal functions of cells and the implication of failure or abnormalities in these processes. Research focuses on signalling and genome regulation, particularly the interplay between the two and how epigenetic signals can influence important physiological adaptations during the lifespan of an organism. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and healthier ageing. www.babraham.ac.uk
* The Biotechnology and Biological Sciences Research Council (BBSRC) invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.
Funded by Government, and with an annual budget of around 445M, we support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.
For more information about BBSRC, our science and our impact see: www.bbsrc.ac.uk
For more information about BBSRC strategically funded institutes see: www.bbsrc.ac.uk/institutes
* The Oxford Biobank is a resource for medical research into common diseases like diabetes, obesity and cardiovascular disease, with detailed data on over 5,000 healthy men and women aged 30 and living in Oxfordshire. All participants have undergone a detailed examination at a screening visit, donated DNA and given informed consent.
http://www.oxfordbiobank.org.uk/
* Oxford University's Medical Sciences Division is one of the largest biomedical research centres in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine, and it is home to the UK's top-ranked medical school.
From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery.
A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu. Oxford is also renowned for its large-scale studies which examine the role of factors such as smoking, alcohol and diet on cancer, heart disease and other conditions.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Single gene cause of insulin sensitivity may offer insight for treating diabetesPublic release date: 12-Sep-2012 [ | E-mail | Share ]
Contact: University of Oxford press office press.office@admin.ox.ac.uk 44-186-528-0530 University of Oxford
The first single gene cause of increased sensitivity to the hormone insulin has been discovered by a team of Oxford University researchers.
The opposite condition insulin resistance is a common feature of type 2 diabetes, so finding this cause of insulin sensitivity could offer new opportunities for pursuing novel treatments for diabetes.
Although mutations in the PTEN gene cause a rare condition with increased risk of cancer, the biological pathways the gene is involved in could offer promising targets for new drugs.
The Oxford University researchers, along with colleagues at the Babraham Institute in Cambridge, UK, and the Churchill Hospital in Oxford, UK, report their findings in the New England Journal of Medicine. The study was funded by the Wellcome Trust, the Medical Research Council, the National Institute for Health Research Oxford Biomedical Research Centre, and the Biotechnology and Biological Sciences Research Council.
'Insulin resistance is a major feature of type 2 diabetes,' says Dr Anna Gloyn of the Oxford Centre for Diabetes, Endocrinology and Metabolism at the University of Oxford, who led the work. 'The insulin-producing cells in the pancreas may be working hard and pumping out lots of insulin, but the body's cells no longer respond.
'Finding a genetic cause of the opposite insulin sensitivity gives us a new window on the biological processes involved. Such understanding could be important in developing new drugs that restore insulin sensitivity in type 2 diabetes.'
The PTEN gene encodes for an enzyme that is part of the insulin signalling pathway in the body. It is known to have a role in controlling the body's metabolism, and to play a part in cell growth. The Oxford team was interested in learning more about this dual role.
There is an inherited genetic condition called Cowden syndrome caused by faults in the PTEN gene. It is very rare and is thought to affect perhaps one in 200,000 people, with around 300 people with the condition in the UK. PTEN's role in cell growth sees people with Cowden syndrome develop many benign polyps in their skin, mouth and bowel, and have a higher risk than the general population of developing breast cancer, thyroid cancer and womb cancer.
'PTEN is a gene that is heavily involved in processes for both cell growth and metabolism,' says first author Dr Aparna Pal of the University of Oxford. 'Given PTEN's dual role, we were interested in understanding the metabolic profile of people with Cowden syndrome. It was possible that mutations in PTEN could improve metabolism.'
The team carried out glucose tolerance tests with 15 people with Cowden syndrome and 15 matched controls. Those with Cowden syndrome had significantly higher insulin sensitivity. In collaboration with their colleagues at the Babraham Institute, the team showed that this was caused by increased activity in the insulin signalling pathway.
The researchers also noticed that the body mass index of those with Cowden syndrome appeared greater than the controls. They carried out a comparison with a much larger control group of over 2,000 individuals from the Oxford Biobank, a data and tissue resource for research established by Professor Fredrik Karpe.
This confirmed that those with Cowden syndrome had higher levels of obesity as a group than the controls. The extra body weight appeared to be caused by extra fat, and there were no differences in where the fat was stored compared to controls.
'This was a surprise. Normally insulin sensitivity goes with being lean,' says Professor Karpe.
Dr Gloyn concludes: 'We now know that mutations that inactivate the PTEN gene result in increased cancer risk and obesity, but also increase insulin sensitivity which is very likely to protect against type 2 diabetes.
'The study shows how intimately the biological pathways governing cell growth and metabolism are linked. We need to thoroughly understand these pathways to identify which genes to target in the development of new drugs.'
She adds: 'While there are promising research avenues to pursue here, in the meantime the best way to avoid diabetes remains exercising more and eating less.'
###
Notes to Editors
* Approximately 2.9 million people are affected by diabetes in the UK, and there may be around a further 850,000 people with undiagnosed diabetes. Left untreated, diabetes can cause many different health problems including heart disease, stroke, nerve damage and blindness. Even a mildly raised glucose level can have damaging effects in the long-term.
Type 2 diabetes is by far the most common form of the disease. In the UK, about 90% of all adults with diabetes have type 2 diabetes. It occurs when the body does not produce enough insulin to control the level of glucose in the blood, and when the body is unable to use the insulin that is produced effectively. It is this second feature of type 2 diabetes that tends to be known as 'insulin resistance'. Insulin resistance is often connected with obesity.
* The paper 'PTEN mutations cause constitutive insulin sensitivity and obesity in humans' is to be published in the New England Journal of Medicine with an embargo of 22:00 UK time / 17:00 US Eastern time on Wednesday 12 September 2012.
* For almost 100 years the Medical Research Council has improved the health of people in the UK and around the world by supporting the highest quality science. The MRC invests in world-class scientists. It has produced 29 Nobel Prize winners and sustains a flourishing environment for internationally recognised research. The MRC focuses on making an impact and provides the financial muscle and scientific expertise behind medical breakthroughs, including one of the first antibiotics penicillin, the structure of DNA and the lethal link between smoking and cancer. Today MRC funded scientists tackle research into the major health challenges of the 21st century. www.mrc.ac.uk
* The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. www.wellcome.ac.uk
* The NIHR Oxford Biomedical Research Centre is funded by the National Institute for Health Research, and is a partnership between the Oxford University Hospitals Trust and the University of Oxford. The NIHR provides the NHS with the support and infrastructure it needs to conduct first-class research funded by the Government and its partners alongside high-quality patient care, education and training. Its aim is to support outstanding individuals (both leaders and collaborators), working in world class facilities (both NHS and university), and conducting leading edge research focused on the needs of patients.
* The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government's strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit the NIHR website (www.nihr.ac.uk). The views expressed in this news release are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
* The Babraham Institute, which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC), undertakes international quality life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. The institute received 22.4M investment from BBSRC in 2010-11. The Institute's research provides greater understanding of the biological events that underlie the normal functions of cells and the implication of failure or abnormalities in these processes. Research focuses on signalling and genome regulation, particularly the interplay between the two and how epigenetic signals can influence important physiological adaptations during the lifespan of an organism. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and healthier ageing. www.babraham.ac.uk
* The Biotechnology and Biological Sciences Research Council (BBSRC) invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.
Funded by Government, and with an annual budget of around 445M, we support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.
For more information about BBSRC, our science and our impact see: www.bbsrc.ac.uk
For more information about BBSRC strategically funded institutes see: www.bbsrc.ac.uk/institutes
* The Oxford Biobank is a resource for medical research into common diseases like diabetes, obesity and cardiovascular disease, with detailed data on over 5,000 healthy men and women aged 30 and living in Oxfordshire. All participants have undergone a detailed examination at a screening visit, donated DNA and given informed consent.
http://www.oxfordbiobank.org.uk/
* Oxford University's Medical Sciences Division is one of the largest biomedical research centres in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine, and it is home to the UK's top-ranked medical school.
From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery.
A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu. Oxford is also renowned for its large-scale studies which examine the role of factors such as smoking, alcohol and diet on cancer, heart disease and other conditions.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
(Reuters) - The music industry won the latest round on Tuesday in its long-running legal battle against a woman accused of illegally downloading and sharing two dozen songs on the Kazaa peer-to-peer network.
The 8th U.S. Circuit Court of Appeals in St. Paul, Minnesota, reinstated a $222,000 jury verdict against Jammie Thomas-Rasset, rejecting her arguments that the damages award was excessive and violated her due process rights under the U.S. Constitution.
The decision is the latest to address the music industry's ability to use the Copyright Act to pursue individuals who illegally download music from the Internet. The law allows copyright owners to recover damages between $750 and $150,000 per infringed work.
Thomas-Rasset, from Brainerd, Minnesota, was one of 18,000 individuals sued by the Recording Industry Association of America between 2003 and 2008 in a legal assault meant to discourage people from illegally downloading songs from sites like Kazaa.
The industry organization accused her of illegally downloading more than 1,700 files. After failing to reach a settlement, the association sued Thomas-Rasset in 2006 over 24 songs on behalf of six major record labels, including Sony BMG Music Entertainment, UMG Recordings Inc and Arista Records.
The case has followed a circuitous path. Thomas-Rasset lost her first trial in 2007 and was ordered to pay $222,000, only to have the court throw out the verdict because of a faulty jury instruction.
At her second trial, Thomas-Rasset testified that her ex-boyfriend or sons, then 8 and 10, were most likely responsible for downloading and distributing the songs. The jury awarded the record labels $1.92 million in damages. But the court lowered the damages to $54,000, calling the jury's award "shocking."
Instead of accepting the lowered amount, the record companies exercised their right to a new trial, and a third jury awarded the music industry $1.5 million in damages. The district court again ruled that the maximum amount allowed by due process was only $54,000. The recording companies appealed.
On Tuesday, a unanimous three-judge panel of the 8th Circuit reinstated the original $222,000 in damages that the first jury had awarded.
The $222,000 award was not "so severe and oppressive" as to violate the Constitution, Judge Steven Colloton wrote for the panel. Rather, the amount, equivalent to $9,250 per song, was at the lower end of the $750 to $150,000 range that Congress established.
Thomas-Rasset argued that if the labels had sued her over 1,000 songs, the damages would be clearly excessive at over $9 million. But the panel refused to extrapolate.
"If and when a jury returns a multi-million dollar award for noncommercial online copyright infringement, then there will be time enough to consider it," Colloton wrote.
Kiwi Camara, a lawyer for Thomas-Rasset, called the $222,000 damages award "punitive" and out-of-line with the U.S. Supreme Court's rulings. He said he would likely appeal the case to the high court.
The Recording Industry Association of America welcomed the court's decision. We "look forward to putting this case behind us," the organization said in a statement. The group has ended its lawsuit campaign, and now sends warning notices to users caught illegally downloading music.
In a separate case in 2011, the 1st Circuit reinstated a $675,000 judgment against Joel Tenenbaum, a former Boston University student, for 30 charges of illegal downloading. That ruling reversed a trial judge's decision to knock the award down to $67,500.
Tenenbaum appealed that case to the Supreme Court, arguing that the Copyright Act was never meant to be applied to individual consumers. But the Supreme Court declined to hear the case in May, allowing the 1st Circuit decision to stand.
The latest 8th Circuit case is Capitol Records Inc et al v. Thomas-Rasset, No. 11-2820.
(Reporting By Terry Baynes; Editing by Tim Dobbyn)
As rumored, Valve's bringing its digital distribution gaming portal to televisions today with Steam "Big Picture Mode." Kotaku confirms the news this morning that the TV-friendly version of Steam will launch "later today," alongside releasing a slurry of screenshots and impressions. Beyond what we already know about the service -- it's the full Steam we already know and love, albeit with controller-based input -- a variety of new details abound. A built-in web browser, for one, and a new form of text input for controllers which seems to massively trump the usualy QWERTY setup.
The entire store is apparently navigable via controller (though mouse and keyboard still work, if that's your kinda thing), and you can even prioritize games based on what's workable with a gamepad. Does this mean that the long-rumored "Steambox" is headed to living rooms soon? Not so fast, says Valve. "We really don't have a road map. And we think we're going to learn a tremendous amount through this first release."
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_v5o4cIaHoCVZc1Y0Ct580LtPWMYMg1rRkLVgjAslSnb5y_P-mS1fzGDsujuaWr2Ydaydu14FcTV8jP5abkFfz2Ud-CFvVyw3xwrXYEq38=s0-d){kind=small}
Public release date: 12-Sep-2012
Share ] 
